Analysis Note

To view the Certificate of Analysis for this product, please visit www.cytiva.com.

Features and Benefits

Novel, alkali-tolerant rProtein A ligand withstands rigorous CIP and sanitization procedures with 0.1 to 0.5 M NaOH. Reduces the risk of product contamination and carryover Improves product quality and reduces overall costs Novel ligand design gives enhanced protease resistance resulting in lower ligand leakage Generic elution profile for different monoclonal antibodies enables platform approach to purification Used in the commercial manufacture of monoclonal antibodies High-flow agarose matrix allows the processing of large feed volumes

General description

MabSelect^™ SuRe^™ is a protein A affinity medium for capturing MAbs at process scale. MabSelect^™ SuRe^™ has an alkali-tolerant rProtein A ligand that allows the use of rigorous and cost-effective CIP and sanitization protocols based on 0.1 to 0.5 M NaOH. Further, the ligand is protease stable leading to lower ligand leakage.MabSelect^™ SuRe^™ is a member of the MabSelect^™ family of affinity chromatography media for the capture of monoclonal antibodies (MAbs) at process scale. MabSelect^™ SuRe^™ shares features and benefits of MabSelect^™ such as a rigid, high-flow agarose matrix that ensures excellent pressure/flow properties, low non-specific binding that leads to low impurity levels in the eluate pool, and an oriented ligand coupling for optimal binding capacity. In addition, MabSelect^™ SuRe^™ features an alkali-tolerant rProtein A ligand. This ligand provides greater stability than conventional protein A-based media in the alkaline conditions used in cleaning-in-place (CIP) and sanitization protocols. The enhanced alkali stability of MabSelect^™ SuRe^™ improves process economy and product quality; cleaning can be performed with cost-effective reagents such as sodium hydroxide eliminating the need for expensive and hazardous cleaning agents such as Gua-HCl.The novel ligand construct of MabSelect^™ SuRe^™ has been proven to have an increased stability towards proteases. Therefore, the level of leakage of the MabSelect^™ SuRe^™ ligand during elution is low. MabSelect^™ SuRe^™ has been demonstrated to give generic elution conditions for different monoclonal antibodies, which is an advantage when designing generic purification platform processes. This feature is also correlated to the construction of the MabSelect^™ SuRe^™ ligand.MabSelect^™ SuRe^™ is available in a range of different bulk pack sizes and convenient pre-packed formats for easy scale-up and process development. As member of the BioProcess media range, MabSelect^™ SuRe^™ meets industrial demands with security of supply and comprehensive technical and regulatory support.

Legal Information

SuRe is a trademark of Cytiva

Free MabSelect SuRe Ligand"MabSelect SuRe Ligand Restricted License" and "Cys-rProtein A Ligand Restricted License" are protected by the following patents and equivalent patents and patent applications in other countries: US 6,399,750 and EP 1123389. A free, non-transferable limited license to use this product for internal analytical purposes only accompanies the purchase of the product from a Cytiva company and its licensed distributors. Any other use will require a separate license from a Cytiva company.

MabSelect is a trademark of Cytiva